Thu. 7 Mar 2024, 7:11am ET
Benzinga
Earnings, News
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.43) by 23.26 percent. This is a 15.38 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $1.50 million which missed the analyst consensus estimate of $1.94 million by 22.63 percent. This is a 79.39 percent decrease over sales of $7.28 million the same period last year.